MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc. (INKT): 3 pipeline candidates · 1 upcoming catalyst · ~17 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
16.8 months
N/A
Lead: Phase 1
3 candidates
1 upcoming, next in ~196d
0 buys · 8 sells (180d)
A transparent, data-derived signal for MiNK Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$60.8M
Cash
$9.5M
Quarterly Burn
$1.7M
Runway
16.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
17
Total value held
$1.8M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 118,728 | $1.3M |
| geode capital management, llc | 17,345 | $183K |
| longbow finance sa | 16,667 | $176K |
| vanguard fiduciary trust co | 8,287 | $87K |
| blackrock, inc. | 6,203 | $65K |
| morgan stanley | 104 | $1K |
| citigroup inc | 91 | $958 |
| northwestern mutual wealth management co | 18 | $190 |
| bnp paribas financial markets | 16 | $168 |
| game plan financial advisors, llc | 16 | $168 |
Showing top 10 of 17 institutional holders of MiNK Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in MiNK Therapeutics, Inc.'s pipeline?
MiNK Therapeutics, Inc. (INKT) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is MiNK Therapeutics, Inc.'s lead drug candidate?
MiNK Therapeutics, Inc.'s most advanced tracked candidate is agent-797 (Phase 1) for Respiratory Distress Syndrome, Adult; Pneumonia.
What is MiNK Therapeutics, Inc.'s next catalyst?
MiNK Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: agent-797" — expected December 31, 2026.
What is MiNK Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, MiNK Therapeutics, Inc. has approximately 16.8 months of cash runway.
What is MiNK Therapeutics, Inc.'s market capitalization?
MiNK Therapeutics, Inc.'s market capitalization is approximately $60.8M.
Get the full picture on MiNK Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.